featured
Glucose Level–Lowering Effects and Safety of Low vs Standard Dose of Lobeglitazone in Patients With T2D With Inadequate Control on Metformin and DPP4 Therapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Diabetes, Obesity & Metabolism
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A double-blind, Randomized controlled trial on glucose-lowering EFfects and safety of adding 0.25 or 0.5 mg lobeglitazone in type 2 diabetes patients with INadequate control on metformin and dipeptidyl peptidase-4 inhibitor therapy: REFIND study
Diabetes Obes Metab 2022 Sep 01;24(9)1800-1809, S Ryang, SS Kim, JC Bae, JM Han, SK Kwon, YI Kim, IS Nam-Goong, ES Kim, MK Kim, CW Lee, S Yoo, G Koh, MJ Kwon, JH Park, IJ KimFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.